Aurinia Pharmaceuticals AUPH Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $298.3M+5.4% | $283.06M+6.5% | $265.81M+2.2% | $260.11M+5.2% | $247.3M+5.2% | ||
| $30.6M-6.3% | $32.67M+11.0% | $29.42M+7.9% | $27.28M-6.2% | $29.07M+2.9% | ||
| $267.7M+6.9% | $250.39M+5.9% | $236.39M+1.5% | $232.84M+6.7% | $218.23M+5.5% | ||
| 89.7%+1.3pp | 88.5%-0.5pp | 88.9%-0.6pp | 89.5%+1.3pp | 88.2%+0.3pp | ||
| $34.23M+5.3% | $32.51M+9.4% | $29.72M+22.1% | $24.33M+16.0% | $20.98M+0.9% | ||
| $103.48M+1.7% | $101.79M-7.1% | $109.57M-12.9% | $125.76M-13.1% | $144.67M-15.9% | ||
| $19.41M-0.2% | $19.45M0.0% | $19.45M-0.1% | $19.48M+0.1% | $19.45M0.0% | ||
| $114K-93.1% | $1.65M-90.3% | $17M0.0% | $17M-5.3% | $17.96M-22.3% | ||
| —— | —— | -$10.1M+26.5% | -$13.74M-227% | -$4.21M-197% | ||
| $173.81M-2.4% | $178.14M-9.0% | $195.8M-5.9% | $208.1M-4.0% | $216.88M-9.6% | ||
| $124.49M+18.7% | $104.91M+49.9% | $70.01M+34.6% | $52.01M+71.0% | $30.41M+749% | ||
| 41.7%+4.7pp | 37.1%+10.7pp | 26.3%+6.3pp | 20%+7.7pp | 12.3%+14.3pp | ||
| $4.28M-1.3% | $4.33M-2.2% | $4.43M-2.4% | $4.54M-1.8% | $4.62M-4.5% | ||
| $13.52M-0.4% | $13.57M-3.5% | $14.06M-6.3% | $15.01M-6.2% | $16.01M-5.6% | ||
| $133.73M+17.1% | $114.16M+43.3% | $79.64M+27.5% | $62.49M+49.5% | $41.81M+461% | ||
| -$164.48M+4.9% | -$173.05M— | —— | —— | —— | ||
| $298.21M+3.8% | $287.2M+269% | $77.84M+28.4% | $60.64M+52.2% | $39.85M+593% | ||
| 100%-1.5pp | 101.5%+72.2pp | 29.3%+6.0pp | 23.3%+7.2pp | 16.1%+13.7pp | ||
| $2.17+4.3% | $2.08+271% | $0.56+30.2% | $0.43+53.6% | $0.28+460% | ||
| $2.26+4.1% | $2.17+274% | $0.58+31.8% | $0.44+51.7% | $0.29+480% | ||
| 549.9M-1.0% | 555.4M-1.3% | 562.9M-1.7% | 572.6M-1.1% | 579.2M-0.1% | ||
| 533.4M-1.2% | 540M-1.6% | 548.7M-2.0% | 559.9M-1.5% | 568.4M-0.9% | ||
| $298.16M+3.8% | $287.25M+271% | $77.47M+27.9% | $60.59M+52.0% | $39.87M+583% | ||
| —— | —— | -$10.1M+26.5% | -$13.74M-227% | -$4.21M-197% | ||
| $298.3M+5.4% | $283.06M+6.5% | $265.81M+2.2% | $260.11M+5.2% | $247.3M+5.2% | ||
| $124.49M+18.7% | $104.91M+49.9% | $70.01M+34.6% | $52.01M+71.0% | $30.41M+749% | ||
| $143.9M+15.7% | $124.36M+39.0% | $89.45M+25.1% | $71.48M+43.3% | $49.87M+238% | ||
| $143.9M+15.7% | $124.36M+39.0% | $89.45M+25.1% | $71.48M+43.3% | $49.87M+238% | ||
| 48.2%+4.3pp | 43.9%+10.3pp | 33.7%+6.2pp | 27.5%+7.3pp | 20.2%+13.9pp | ||
| $124.49M+18.7% | $104.91M+49.9% | $70.01M+34.6% | $52.01M+71.0% | $30.41M+749% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Aurinia Pharmaceuticals's revenue?
- Aurinia Pharmaceuticals (AUPH) generated $298.3M in revenue over the trailing twelve months, up 20.6% year over year.
- Is Aurinia Pharmaceuticals profitable?
- Aurinia Pharmaceuticals reported $298.2M in net income over the trailing twelve months, a 100.0% net margin.
- What are Aurinia Pharmaceuticals's profit margins?
- Gross margin is 89.7% and operating margin is 41.7%, with a 100.0% net margin.
- What is Aurinia Pharmaceuticals's earnings per share?
- Aurinia Pharmaceuticals's diluted EPS over the trailing twelve months is $2.17.
- Where does Aurinia Pharmaceuticals's income statement data come from?
- Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
